XTL Biopharmaceuticals Ltd. (TLV: XTLB)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
6.10
+1.00 (19.61%)
Dec 22, 2024, 2:01 PM IDT

XTL Biopharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Mar '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Net Income
--1.78-1.350.44-2.95-0.76
Upgrade
Depreciation & Amortization
--000-
Upgrade
Loss (Gain) From Sale of Investments
-1.021.53-0.75-0.140.57
Upgrade
Stock-Based Compensation
-00.010.040.050.01
Upgrade
Other Operating Activities
--0.01-1.08-0.722.15-0.67
Upgrade
Change in Accounts Payable
-0.02-0.04-0.020.02-0.02
Upgrade
Change in Other Net Operating Assets
-0.050.03-0.030.02-0.03
Upgrade
Operating Cash Flow
--0.71-0.9-1.05-0.85-0.91
Upgrade
Capital Expenditures
-----0-0
Upgrade
Investment in Securities
-----2.02
Upgrade
Other Investing Activities
-0.040.040.010.030.09
Upgrade
Investing Cash Flow
-0.040.040.010.032.11
Upgrade
Issuance of Common Stock
---0.39--
Upgrade
Financing Cash Flow
---0.39--
Upgrade
Foreign Exchange Rate Adjustments
--0.03-0.01-0.01-0.01-0
Upgrade
Net Cash Flow
--0.69-0.88-0.66-0.821.2
Upgrade
Free Cash Flow
--0.71-0.9-1.05-0.85-0.91
Upgrade
Free Cash Flow Per Share
--0.00-0.00-0.00-0.00-0.00
Upgrade
Levered Free Cash Flow
--0.41-0.55-0.66-0.5-0.57
Upgrade
Unlevered Free Cash Flow
--0.41-0.55-0.66-0.5-0.57
Upgrade
Change in Net Working Capital
0.16-0.060.020.05-0.050.05
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.